Boehringer Ingelheim Hepatitis C Phase III Trials: 85% Of Japanese Show Sustained Viral Response
This article was originally published in PharmAsia News
Executive Summary
In Phase III hepatitis C trials using the protease inhibitor faldaprevir and pegylated interferon ribavirin carried out by Boehringer Ingelheim, 85% of Japanese participants displayed a sustained viral response.